Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...

After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Women-focused healthcare firm Maven Clinic was valued at $1.7 billion after it raised $125 million in its latest funding round led by private markets investment firm StepStone Group , it said on ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

Talkiatry to offer new resources and expand access to care for women experiencing postpartum mental health challenges by virtually connecting them with a provider from the comfort of their own home ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage said it will continue to test dalzanemdor as a treatment for Huntington's disease and expects to report its mid-stage ...

Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the ...

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...

US stock futures traded higher Tuesday, bouncing after the previous session’s losses ahead of more comments from a series of ...